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By Michael Poulsen, Danny Rischin, Euan Walpole, Jennifer Harvey, John Mackintosh, Jill Ainslie, Chris Hamilton, Jacqui Keller,
and Lee Tripcony
Purpose: The effectiveness of synchronous carboplatin,
etoposide, and radiation therapy was prospectively as-
sessed in a group of patients with high-risk Merkel cell
carcinoma (MCC) of the skin.
Patients and Methods: Patients were eligible if they had
disease localized to the primary site and nodes, and were
required to have at least one of the following high risk
features: recurrence after initial therapy, involved nodes,
primary tumor size greater than 1 cm, gross residual
disease after surgery, or occult primary with nodes. Ra-
diation was delivered to the primary site and nodes to a
dose of 50 Gy in 25 fractions over 5 weeks and synchro-
nous carboplatin (area under the curve, 4.5) and intrave-
nous etoposide 80 mg/m2 days 1 to 3 was given in weeks
1, 4, 7, and 10. The median age of the group was 67
(range, 43–86) years, and there were 39 males and
14 females. Involved nodes (stage II) were present in
33 cases (62%). The sites involved were head and
neck (22 patients), occult primary (13 patients), upper
limb (eight patients), lower limb (eight patients), and
trunk (two patients).
Results: Fifty-three patients were entered between
1996 and 2001. The median potential follow-up was 48
months. There were no treatment related deaths. The
3-year overall survival, locoregional control, and distant
control were 76%, 75%, and 76%, respectively. Tumor
site and the presence of nodes were factors that were
predictive for local control and survival. Multivariate
analysis indicated that the major factor influencing sur-
vival was the presence of nodes; however, this was not a
significant factor in locoregional control.
Conclusion: High levels of locoregional control and sur-
vival have been achieved with the addition of chemother-
apy to radiation treatment for high-risk MCC of the skin. The
role of chemoradiotherapy for high-risk MCC warrants fur-
ther investigation.
J Clin Oncol 21:4371-4376. © 2003 by American
Society of Clinical Oncology.
THE TRANS-TASMAN Radiation Oncology Group em-barked on a phase II study of synchronous chemoradio-
therapy in high-risk Merkel cell carcinoma (MCC) of the skin in
1996. High risk MCC was defined as primary tumors more than
1 cm in diameter, and/or the presence of in-transit or nodal
metastases, and/or locally or regionally lymphatic recurrent
tumor, but with no evidence of distant disease. The use of
radiotherapy in locoregional control of MCC is considered
standard treatment, although the optimal combination of surgery
and radiotherapy is contentious. The rationale for investigating
synchronous chemoradiotherapy was based on the tumor’s high
metastatic potential, its inherent chemosensitivity and radiosen-
sitivity, and its similarity to small-cell carcinoma of the lung.
This approach has become standard practice in the management
of small-cell carcinoma of the lung, which has similar histologic
morphology and biologic behavior to MCC.
The main aims of the study were to investigate the efficiency
and safety of chemotherapy in MCC, and to determine whether
this regimen could be delivered in a multi-institutional setting.
This is the first report in the literature, using a standard
approach to MCC of the skin, that incorporates chemotherapy
and radiation. Most reports have been from individual institu-
tions and suffer from a lack of power because of the small
numbers and inconsistent treatment regimens.
A preliminary report on the acute and late toxicity for this
protocol was published after the first 40 patients had been
treated.1 We now report the overall survival, locoregional
control, and distant metastases control rates achieved with the
regimen, as well as updating the toxicity in all 53 patients treated
with this protocol.
PATIENTS AND METHODS
Trial Design
Patients were only eligible for this study if they had disease confined to the
primary or nodes region, and they were at high-risk of recurrence. This was
defined as having at least one of the following criteria: primary size greater
than 1 cm, involved nodes, recurrence following initial surgery (providing
the recurrence was outside of the previous radiation field), gross residual
disease after surgery, or occult primary with nodes.
In addition, the following eligibility criteria were required to be met:
biopsy proven MCC confined to the primary and regional nodes, Eastern
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Cooperative Oncology Group performance status of 0 to 2, no previous
malignancy in the past 5 years other than nonmelanomatous skin cancer,
hemoglobin  10g/dL, neutrophils  2  109/L, platelets  100  109/L,
and normal renal function (glomerular filtration rate  50 mL/min). The
protocol was approved by each of the hospital ethics committees and
written informed consent was obtained on all patients. Activation of the
trial occurred in 1996 and closure occurred in 2001. The close out date for
the analysis was July 8, 2002.
Pretreatment Evaluation
Paraffin sections were required to be reviewed at the treating hospital to
confirm the diagnosis. All patients were evaluated with computed tomogra-
phy of the chest and abdomen to exclude distant metastatic sites. Full blood
count, electrolytes and liver function tests were also performed. Tumor
extent was documented on diagrams.
Treatment
Surgery was often performed before referral to the oncology department.
Furthermore, the extent of surgery was at the discretion of the local
institution as it was thought impracticable to standardize in a heterogeneous
disease population, across multiple institutions, and considered a less
important factor in achieving locoregional control than the application of
the trial’s chemoradiotherapy regimen. However, it was recommended
that the primary site be resected with clear margins where achievable.
Wide surgical clearance of the primary site was not required nor
recommended, and it was not a prerequisite to have nodal disease resected
or positive margins re-excised.
Radiotherapy
The primary site was encompassed with a generous margin (3 to 5 cm)
where possible. Wax build up (appropriate to photon or electron energy) was
applied to all scars and primary and in-transit areas to ensure adequate dose
to the surrounding dermal lymphatics. The draining lymph nodes were
treated in continuity with the primary site, provided the nodes were within 20
cm of the primary.
A dose of 50 Gy (Internation Commission on Radiation Units and
Measurements 50) in 25 fractions over 5 weeks was prescribed to macro-
scopically involved areas or to the operative bed. Electron doses were
specified at the 90% isodose line. A shrinking field technique was used after
46 Gy if field volumes were large. Clinically uninvolved areas were treated
to a dose of 45 Gy in 25 fractions over 5 weeks (eg, clinically uninvolved
nodal areas that are outside the surgical volume). A dose reduction to 45 Gy
was recommended for lesions located below the knee or areas where 50 Gy
was thought to be poorly tolerated (eg, around the inguinal nodes or adjacent
to the orbit).
Chemotherapy
Chemotherapy was administered during weeks 1 and 4 of radiotherapy,
and then 2 weeks and 5 weeks after radiotherapy (weeks 7 and 10).
Carboplatin dose was calculated according to the Calvert formula,2 and
was given intravenously on day 1 of each course of chemotherapy.
Initially an area under the curve of 5 was recommended, but this was
dropped to 4.5 in April 1998 when an interim review suggested that there
were high levels of neutropenia.
Glomerular filtration rate was calculated according to the Cockcroft and
Gault Formula or by measurement of Tc-99m DTPA clearance. The latter
method, which was being used at one site, was abandoned as it resulted in
higher doses of carboplatin and therefore, lack of uniformity in dose
calculations between sites. Etoposide was given in a dose of 80 mg/m2/d
intravenously days 1 to 3. Once the radiation was completed, a further two
cycles of chemotherapy were given in weeks 7 and 10, resulting in a total of
four cycles. It was specified that the pretreatment neutrophil count should
be  1.5 109/L and platelet count should be  100  109/L. Blood counts
were required weekly during the chemoradiotherapy. If the neutrophil or
platelet count had not recovered by week 4, then the remainder of the
chemotherapy was to be given once every 4 weeks (weeks 1, 5, 9, 13).
Providing the counts had recovered, the option of once every 3 weeks
chemotherapy remained. A dose reduction of carboplatin to AUC 4 and
etoposide dose reduction of 20% was recommended if there was any grade
3 or 4 nonhematologic toxicity (excluding skin, hair loss, nausea, vomiting),
grade 4 neutropenia, or fever with grade 3 or 4 neutropenia. Weight change
of greater than 5% or a change in creatinine greater than 10 mol/L required
recalculation of the chemotherapy doses.
Quality Assurance
A detailed audit was performed on the first 20 patients to examine protocol
compliance. This included a review of the clinical, chemotherapy, and
radiation details, and an independent review panel outside of the treatment
institution reviewed the pretreatment investigations, GFR calculations, and
protocol violations for chemotherapy and radiotherapy.
Follow-Up
Acute toxicity was assessed weekly during the radiation therapy and
during the third and fourth courses of chemotherapy. Thereafter, reviews
monitoring disease status and long-term toxicity were conducted at minimum
frequency of every 6 months until death.
Outcome Variables
The close out date for this analysis was July 8, 2002. Survival, locore-
gional control, and distant control were measured from the date of registra-
tion, and toxicity was measured from the start of the radiation treatment.
WHO toxicity grading was applied to report acute toxicity. Late toxicity was
scored using the Radiation Therapy Oncology Group/European Organization
for Research and Treatment of Cancer system. Toxicity was plotted as
actuarial cumulative probability over time. Patients were censored at death or
date of last follow-up. Time to toxicity was defined as time from treatment
start to the occurrence of the specified grade of toxicity. Late toxicity was
graded provided a period of 168 days had elapsed from the start of treatment.
Statistical Methods
A generalized linear interactive modeling package was used to examine
the data. 2 tests were used to compare proportions. All time-to-event curves
were calculated using the actuarial method of Kaplan and Meier and were
compared using the log-rank test. Overall survival considered any death as an
event (including those from intercurrent illnesses). Locoregional control was
defined as the proportion of patients who did not develop failure in the primary
site, regional nodes or in-transit areas, with censoring of events occurring at
death without locoregional failure. Distant control was defined as the proportion
of patients not developing hematogenous spread, with censoring occurring at
death in the absence of distant failure. Cox’s proportional hazards model was
used to derive hazards ratios for prognostic variables using the end points of
overall survival, locoregional control, and distant control.
RESULTS
Patient Characteristics
A total of 53 patients were registered from six institutions in
Australia. No patients were excluded from the analysis. The
median potential follow-up time was 48 (range, 11–70) months
and no patients were lost to follow-up. Twelve patients regis-
tered in the study presented with recurrence and had received
prior therapy. The remaining 41 all received chemoradiotherapy
as their initial treatment. No patients had received prior radiation
treatment. In total, the chemoradiotherapy was given as an
adjuvant treatment in 38 patients (72%) and as definitive
therapeutic treatment in 15 patients (28%). The distribution of
baseline characteristics is summarized in Table 1.
4372 POULSEN ET AL
Downloaded from ascopubs.org by University of Queensland on February 9, 2017 from 130.102.082.116
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Survival Analyses
The 3 year overall survival was 76% (95% CI, 63.5 to 88.7;
Fig 1A). Relapse free survival was 65% (95% CI, 50.8 to 78.5)
and distant control was achieved in 76% (95% CI, 63.4 to 88.7)
of patients (Fig 1B). The 3-year survival for those with occult
and known primary sites were 83% (95%CI, 61.5 to 100) and
74% (95% CI, 58.7 to 88.8), and distant control rates were 91%
(95% CI, 73.9 to 100) and 56% (95% CI, 55.9 to 86.9),
respectively.
Univariate analyses were performed by splitting the groups
according to age, nodal status, site, and presence of gross
residual disease at the time of chemoradiotherapy. The 3-year
survival for patients with involved nodes compared with no
nodal involvement was 66% and 93% (P  .27). Patients who
had gross residual disease at the time of chemoradiotherapy had
a poorer outcome of 45%, compared to 90% (P  .07).
Locoregional Control
Two patients had persistent disease at the end of chemoradio-
therapy, both with primary site in the lower limb. The actuarial
locoregional control at 3 years was 75% (95% CI, 62.7 to 87.5;
Table 1. Distribution of Baseline Characteristics (N  53)
Parameter
No. of
Patients
Median age, years 67
Range 43-86
Sex
Male 39
Female 14
Site
Head and neck 22
Upper limb 8
Lower limb 8
Trunk 2
Occult 13
T Stage
Tx or unknown 14
T1 28
T2 11
N Stage
N0 20
N1 21
N2 12
ECOG
0 41
1 10
2 1
u/k 1
Surgery to primary site
Nil 13
Excision/clear margins 28
Excision/close margins 5
Excision/involved margins 6
Gross residual 1
Surgery to nodes
Nil 28
Biopsy 6
Nodectomy 4
Radical removal 15
Radiation dose, Gy
Median 50
Range 44-60
Surgery to RT, days
Median 47
Range 14-872
Chemotherapy courses completed
1 2
2 3
3 2
4 46
Abbreviations: ECOG, Eastern Cooperative Oncology Group;
u/k, unknown; RT, radiotherapy.
Fig 1. 3-year actuarial curves. The numbers of patients at risk for an event are
tabulated below the plot. (A) Overall survival; (B) distant control; (C) locoregional
survival.
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Fig 1C). Locoregional control rates for occult and known
primaries were 91% (95% CI, 73.9 to 100) and 70% (95% CI,
55.2 to 85.3), respectively. The locoregional control rate for the
38 patients who received adjuvant chemoradiotherapy was 77%
(95% CI, 46 to 95.3), and for the 15 patients who received
therapeutic chemoradiotherapy, the locoregional control rate was
71% (95% CI, 62.8 to 91.2). Locoregional failure at the primary
site, in-transit areas, or the draining nodes occurred in nine of the
53 patients; seven of these occurred in the absence of distant
disease and two in the presence of distant disease. The median
time to locoregional recurrence was 187 (range, 0–544) days.
Acute Toxicity
Grade 3 and 4 reactions occurred in the skin in 34 patients
(64%). Four of these reactions were grade 4. Neutropenia of
grade 3 or higher occurred in 30 patients (57%) and febrile
neutropenia occurred in 19 patients (35%). These results are
tabulated in Table 2. Febrile neutropenia was most likely to
occur at the nadir of the second cycle of chemotherapy when the
radiation reactions in the skin or mucosa were most severe,
providing a possible portal of entry for infection.
Late Toxicity
Grade 3 or higher late skin and subcutaneous toxicity was
15% and 13%, respectively, at 3 years. One patient developed
acute arterial obstruction in the femoral vessels at the site of an
inguinal radiotherapy field 4 years after registration in the study.
The inguinal node had been resected before radiotherapy and
radiotherapy/chemotherapy was delivered to the involved ingui-
nal and iliac nodes as per protocol. This patient had experienced
a grade 4 skin reaction in the groin and had severe late and
subcutaneous changes present in the radiation field. She was also
noted to have risk factors for peripheral vascular disease.
The obstruction was successfully treated with a bypass pro-
cedure but she went on to have an amputation 18 months later
when the graft occluded.
Multivariate Analysis
The most powerful prognostic factor for overall survival was
the presence of nodes. The hazard ratio for N1 and N2 disease
was 4.34 and 76.71 respectively, the latter being statistically
significant (P  .001). The presence of gross disease at the time
of chemoradiotherapy had a hazard ratio of 0.82 indicating no
increased risk of death as a result of incomplete disease resection
before chemoradiotherapy.
The presence of nodes was not significant when locoregional
control was used as an end point. Primary sites in the lower limb
had a significant risk of locoregional failure with a hazard ratio
of 12.67 (P  .002). The results of the Cox’s proportional
hazards modeling have been summarized in Table 3 and 4.
Quality Assurance
An audit of the first 20 patients indicated that the percentage
of patients treated strictly according to protocol (with no varia-
tion in timing or dose) was 50% for chemotherapy and 55% for
radiotherapy. Compliance with the recommended radiation dose
was checked in all 53 patients. Patients were treated as per
protocol (defined as  5%) in 83% of cases. Minor deviations in
dose occurred in 9.5% of cases. Major dose deviations of an
acceptable nature occurred in 7.5% of cases. There were no
major deviations in dose of an unacceptable nature.
All four chemotherapy doses were given in 46 patients. There
were two patients who received only one cycle, three that
received two cycles, and two patients that received three cycles.
In total there were 145 gaps or time intervals between the
chemotherapy cycles. One hundred and thirty one (90.3%) of
these time intervals were as per protocol ( 27 days). Prolon-
Table 2. Grades of Acute Reactions
Grade
0 1 2 3 4
Skin 0 5 14 30 4
Nausea 13 29 6 5 0
Neutrophils 2 8 13 12 18
Hemoglobin 34 13 4 2 0
Platelets 39 6 3 4 1
Table 3. Cox’s Proportional Hazards Modeling for Overall Survival
Covariate
Hazard
Ratio 95% CI P
Age
 67 years 1
 67 years 3.09 0.87 to 10.99 .08
Head and neck 1
Upper limb 0.24 0.04 to 1.53 .13
Lower limb 4.18 0.83 to 21.16 .08
Trunk 4.41 0.45 to 43.57 .20
Occult 0.02 0.00 to 0.22 .002
N stage
N0 1
N1 4.34 0.8 to 23.46 .09
N2 76.71 5.76 to 1021 .001
No gross residual disease 1
Gross residual disease 0.82 0.21 to 3.23 .78
Table 4. Cox’s Proportional Hazards Modeling for Locoregional Control
Covariate
Hazard
Ratio 95% CI P
Age
 67 years 1
 67 years 0.37 0.11 to 1.25 .11
Head and neck 1
Upper limb 0.3 0.03 to 3.01 .31
Lower limb 12.67 2.59 to 61.86 .002
Trunk 0.01 0.00 to 13555243 .67
Occult 0.09 0.01 to 1.19 .07
N stage
N0 1
N1 1.33 0.20 to 8.92 .77
N2 6.46 0.51 to 82.36 .15
No gross residual disease 1
Gross residual disease 1.26 0.20 to 7.71 .80
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gations of 8 to 14 days beyond the recommended interval
occurred in 12 (8.3%) occasions and on two occasions there were
prolongations of greater than 28 days.
DISCUSSION
Unlike previous reports in the literature, this group of patients
has been prospectively assessed and treated with a uniform
protocol of chemoradiotherapy with curative intent. There has
been a high level of compliance in the delivery of the radiation
dose and 87% of the patients were able to complete all four
courses of chemotherapy. Only 9.7% of patients had protracted
intervals greater than the recommendations in the protocol.
The extent of the surgical treatment of primary and nodal
disease could not be rigorously standardized in this trial because
of the heterogeneity of disease status and the variety of anatomic
locations in this rare skin malignancy. Furthermore, surgery was
frequently performed before referral to the oncologist, and there
is no evidence that further radical surgery would confer any
benefit to locoregional control over and above this radical
chemoradiotherapy trial regimen. Conversely, delaying the che-
moradiotherapy treatment to undertake further radical surgery
(that was likely to reduce tolerance of the trial regimen) was
considered potentially detrimental to tumor control by reducing
treatment efficacy.
Although the treatment protocol was standardized for the
chemotherapy and radiation therapy, the patient population was
relatively heterogeneous in terms of patient and tumor parame-
ters. The study only included patients who were perceived to be
at high risk of recurrence, but they had to be fit enough to tolerate
chemoradiation. All reported Merkel cell carcinoma studies
suffer from some degree of heterogeneity in the patient popula-
tion, and this limits the ability to compare since any differences
detected may be as a result of patient selection rather than the
treatment itself. The heterogeneity in this study should be less
than others as we have confined our study group to patients that
have high-risk locoregional disease, but good performance
status; that is, patients with low-risk disease, distant metastatic
disease, or poor performance status are excluded. Nevertheless,
it is acknowledged that there are real limitations in comparing
these results with others in the literature.
Prognostic factors have been well described in previous
reports3-12 and a recent review by Goessling et al13 summarizes
these. In comparing these results with those reported in the
literature, it is important to match the proportion of patients with
adverse prognostic variables, the most important being the
presence of nodal metastases.3-7 Thirty-three patients (62%)
registered on this study had involved nodes (stage II) at presen-
tation. This contrasts with the literature where the reported
incidence of nodes at presentation varied from 9% to 33%,3-5,8-11
and confirms the particularly poor prognostic profile of patients
in this trial (being at high risk of disseminated disease).
The 3-year survival of 76% compares favorably with others in
the literature. Meeuwissen et al3 reported 68% 3-year survival
for a group of 80 patients (33% had stage II disease) treated at
the Queensland Radium Institute, and Morrison et al4 achieved
30% 5-year survival for a group of 54 patients (16% had stage II
disease). Other reports claim 63% 5-year survival (20% had
stage II disease);14 58% 3-year survival (26% had stage II
disease);5 64% 5-year survival (31% had stage II disease);6 35%
3-year survival (9% had stage II disease);10 and 40% 5-year
survival (18% had stage II disease).15
Eleven (21%) of 53 patients suffered locoregional failure, and
the 3-year actuarial locoregional control was 75%. In a review of
the literature, Haag et al16 reported that local recurrence devel-
oped in 26% to 44% of patients, and during the course of the
disease, 55% to 66% of patients developed regional node
metastases. Given that 28% of patients had gross disease at either
the primary site or the nodes, and 36% had recurrence before
registering on the study, these figures compare favorably with
those in the literature.
Distant control at 3 years for the whole group was 76%, or
looking at the crude figure, nine (17%) of 53 patients developed
distant metastases. Early reported series quote rates of distant
metastatic disease to be 30%,14,16,17 with some as high as 70%.8
This does suggest that chemotherapy may have had a positive
influence in reducing distant metastatic disease. However, great
caution must be taken in interpreting this data, given the
significant diversity of patients, stages of disease, and various
methods of reporting in these series.
Occult primaries have been reported in a number of MCC
series. The incidence varies from 0% to 18%,3,4,8,15 and can be
attributed to spontaneous regression of the primary18 or meta-
static neuroendocrine carcinoma from a noncutaneous site. The
incidence in this series was proportionally higher (25%) and may
be as a result of several factors. Excluding patients with
primaries less than 10 mm from entering the study could have
caused a relative increase in numbers with an occult primary.
The hazard ratio for occult primaries was 0.02, indicating that
this was a favorable prognostic variable. This may have biased
the results of this series favorably compared with some of the
historic series. Although the superior outcome in the occult
primary group is counterintuitive, a possible explanation could
be that patients with occult primaries have had an immunologic
response to their cancer.
A detailed report on toxicity was made after the first 40
patients were treated.1 This suggested that the most threatening
side effect was associated with neutropenia. The incidence of
febrile neutropenia was highest after the second cycle of che-
motherapy, which coincided with maximal radiation skin reac-
tions. It is postulated that this provided a portal of entry for
bacteria at a time when the white cell count was low. We are now
embarking on a pilot study aimed at reducing the incidence of
febrile neutropenia. Patients will be treated with radiotherapy to
a dose of 45 to 50 Gy with synchronous weekly carboplatin in a
dose of AUC 2.0 to a maximum of five courses. This will be
followed by three cycles of carboplatin and etoposide in the
same doses in TROG 96:07. If the toxicity of this schedule is
acceptable, it may form the basis of an experimental arm of a
phase III randomized trial. International collaboration will be
required for such as a study. The acceptability of a radiation-
alone arm may cause some difficulties in the future. However,
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this will be the only way to overcome the biases that occur when
retrospective comparisons are made with historical controls.
This prospective phase II study demonstrates that chemora-
diotherapy with curative intent for high risk MCC is tolerable for
the vast majority of patients. Results indicate that despite the
high proportion of patients with nodal metastases and gross
residual disease at the time of chemoradiotherapy, 76% of
patients were alive at 3 years. This survival and favorable
locoregional and distant control rates appear superior to reported
retrospective series in the literature even though it is recognized
that we are comparing a diverse range of patients with MCC.
However, a phase III study is needed if the true magnitude of the
benefit of synchronous chemotherapy is to be defined.
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